Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.52 |
| ▸ | SYK | P43405 | 9/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924588 | 0.92 | SYK (0.51) | JAK2HDAC1HDAC6SYKSRC | |
| SCHEMBL13924585 | 0.92 | SYK (0.50) | JAK2HDAC1HDAC6SYKSRC | |
| SCHEMBL13924586 | 0.89 | SYK (0.48) | JAK2HDAC1HDAC6SYKSRC | |
| SCHEMBL13924587 | 0.87 | SYK (0.58) | JAK2HDAC1HDAC6SYKSRC | |
| SCHEMBL13924582 | 0.82 | SYK (0.58) | JAK2HDAC1HDAC6SYKSRC | |
| SCHEMBL13924577 | 0.81 | SYK (0.64) | SYKSRCZAP70CDK2ABL1 | |
| SCHEMBL13924584 | 0.81 | SYK (0.53) | JAK2SYKSRCZAP70CDK2 | |
| SCHEMBL13924597 | 0.79 | SYK (0.64) | SYKSRCZAP70CDK2ABL1 | |
| SCHEMBL13924591 | 0.79 | SYK (0.55) | JAK2HDAC1HDAC6SYKSRC | |
| SCHEMBL13924599 | 0.78 | SYK (0.65) | SYKSRCZAP70CDK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488727-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488727-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070249645-A1 | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-25 | — | — | US | disclosed |
| US-20070249645-A1 | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-25 | — | — | US | disclosed |
| US-7256190-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256190-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249645-A1 | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE | BTK, AURKC, GSK3B | JAK2 37/4885HDAC1 1448/4885HDAC6 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.